Evidence map›Paper›PMID 36729167›Full record

ArticleClinical and experimental immunology2023

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.

Merryn Voysey, Amy Flaxman, Jeremy Aboagye, Parvinder K Aley, Sandra Belij-Rammerstorfer, Sagida Bibi, Mustapha Bittaye, Federica Cappuccini, Sue Charlton, Elizabeth A Clutterbuck and 27 more

Open access · hybridFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 3 institutions in 1 country.

Merryn VoyseyOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.ORCID 0000-0001-6324-6559
Amy FlaxmanOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.ORCID 0000-0001-6460-1372
Jeremy AboagyeJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Parvinder K AleyOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Sandra Belij-RammerstorferOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Sagida BibiOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Mustapha BittayeJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Federica CappucciniOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Sue CharltonPublic Health England, Porton Down, UK.
Elizabeth A ClutterbuckOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Sophie DaviesJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Christina DoldOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Nick J EdwardsPandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, UK.
Katie J EwerJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0001-9827-9836
Saul N FaustNIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.ORCID 0000-0003-3410-7642
Pedro M FolegattiJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Jamie FowlerJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Ciaran GilbrideJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Sarah C GilbertPandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, UK.
Leila GodfreyOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Bassam HallisPublic Health England, Porton Down, UK.
Holly E HumphriesPublic Health England, Porton Down, UK.
Daniel JenkinPandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, UK.
Simon KerridgeOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Yama F MujadidiOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Emma PlestedOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Maheshi N RamasamyOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Hannah RobinsonOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Helen SandersOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Matthew D SnapeOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Rinn SongOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Kelly M ThomasPublic Health England, Porton Down, UK.
Marta UlaszewskaPandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, UK.
Danielle WoodsOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Daniel WrightJenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Andrew J PollardOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
Teresa LambeOxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
University of Oxford · GBPublic Health England · GBUniversity Hospital Southampton NHS Foundation Trust · GB

Funding

Medical Research Council MC_PC_19055
6 · The paper itself

Abstract

The trajectory of immune responses following the primary dose series determines the decline in vaccine effectiveness over time. Here we report on maintenance of immune responses during the year following a two-dose schedule of ChAdOx1 nCoV-19/AZD1222, in the absence of infection, and also explore the decay of antibody after infection. Total spike-specific IgG antibody titres were lower with two low doses of ChAdOx1 nCoV-19 vaccines (two low doses) (P = 0.0006) than with 2 standard doses (the approved dose) or low dose followed by standard dose vaccines regimens. Longer intervals between first and second doses resulted in higher antibody titres (P < 0.0001); however, there was no evidence that the trajectory of antibody decay differed by interval or by vaccine dose, and the decay of IgG antibody titres followed a similar trajectory after a third dose of ChAdOx1 nCoV-19. Trends in post-infection samples were similar with an initial rapid decay in responses but good persistence of measurable responses thereafter. Extrapolation of antibody data, following two doses of ChAdOx1 nCov-19, demonstrates a slow rate of antibody decay with modelling, suggesting that antibody titres are well maintained for at least 2 years. These data suggest a persistent immune response after two doses of ChAdOx1 nCov-19 which will likely have a positive impact against serious disease and hospitalization.

Indexed as

ChAdOx1 nCoV-19Immunoglobulin GAntibodies, ViralFollow-Up StudiesHumansImmunityRandomized Controlled Trials as TopicVaccinationAntibodies, ViralChAdOx1 nCoV-19Immunoglobulin Gantibodiesanti-viral immunityvaccinationvaccine

Identifiers

PMID36729167
PMCPMC10038323
OpenAlexW4318924150

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read12
identifiers read2
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.